Trimodality Therapy for Malignant Pleural Mesothelioma

May 3, 2011

Primary Outcome Measures:

To determine the overall 5-year survival rate. [ Time Frame: 5-years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
Morbidity
Number of Participants with treatment related deaths as a Measure of Safety and Tolerability [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
Mortality
Recurrence [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Occurence of tumor recurrence

Eligibility & Criteria

Study Population

Patients with malignant pleural mesothelioma prsentint at the Deparment of Thoracic Surgery, HSK Wiesbaden

Inclusion Criteria:

Histologically confirmed diagnosis of MPM (all subtypes)
Clinical T1-3, N0-2, M0 disease.
No prior treatment for MPM.
Adequate renal and liver function
Adequate cardio-pulmonary reserves

Exclusion Criteria:

Patients with unresectable disease
Patients with an active infection that require systemic treatments
Patients with a concurrent active malignancy.
Patients with serious medical illness.

CONTACT INFORMATION

Name*

First Last

Email*

Phone*

Address*

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Have you received a diagnosis?*

Yes

DIAGNOSIS

Diagnosis?*

Date of Diagnosis*

Comments*

This field is for validation purposes and should be left unchanged.

Quick Facts

Accepts Healthy Volunteers
Ages Available for Study
ClinicalTrials.gov Identifier
Collaborators
Contacts(s)
Location(s)
Estimated Enrollment
Estimated Study Start Date
Estimated Primary Completion Dates
Full Title
Genders Eligible for Study
Investigator(s)
Last Updated
Other Contact